|
| related topics |
| {product, liability, claim} |
| {customer, product, revenue} |
| {product, market, service} |
| {stock, price, share} |
| {control, financial, internal} |
| {acquisition, growth, future} |
| {interest, director, officer} |
| {personnel, key, retain} |
| {stock, price, operating} |
| {property, intellectual, protect} |
| {operation, international, foreign} |
|
|
We expect to incur significant operating losses in the near future
Our company is currently dependent on one principal product line to generate revenues
Our company is dependent on one principal customer
Our ability to realize future revenues from the Optiwave 980 is dependent upon Edwards successfully launching this new product into an existing market with a new sales team
Our company is dependent on certain suppliers
We are dependent upon our key personnel and will need to hire additional key personnel in the near future
Our company may be unable to raise needed funds
In order to compete effectively, our current and future products need to gain commercial acceptance
Our primary competitor in TMR may obtain FDA approval to market a new device, the impact of which is uncertain on the future adoption rate of TMR
Rapid technological changes in our industry could make our products obsolete
We must receive and maintain government clearances or approvals in order to market our products
Changes in third party reimbursement for either TMR or cardiac tissue ablation procedures could materially affect future demand for our products
Asserting and defending intellectual property rights may impact our results of operations
We may be subject to product liability lawsuits; our insurance may not be sufficient to cover damages
We are subject to risks associated with international operations
We will soon have to comply with internal controls evaluations and attestation requirements
Because we are incorporated in Canada, you may not be able to enforce judgments against us and our Canadian directors
Our stock price has historically fluctuated and may continue to fluctuate significantly in the future which may result in losses for our investors
The market price of our stock may fall if shareholders sell their stock
We have no intention to pay dividends
Full 10-K form ▸
|
|
| related documents |
| 1013606--3/16/2006--ENDOLOGIX_INC_/DE/ |
| 1013606--3/12/2007--ENDOLOGIX_INC_/DE/ |
| 1050007--11/29/2007--NUTRACEUTICAL_INTERNATIONAL_CORP |
| 1014507--6/1/2006--SCHICK_TECHNOLOGIES_INC |
| 1006195--6/8/2009--MATRIXX_INITIATIVES_INC |
| 890846--5/28/2010--UROPLASTY_INC |
| 943894--3/28/2008--EZENIA_INC |
| 1068874--10/15/2007--IMPLANT_SCIENCES_CORP |
| 1013606--2/29/2008--ENDOLOGIX_INC_/DE/ |
| 874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE |
| 1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP |
| 882873--9/17/2010--UROLOGIX_INC |
| 1050007--11/20/2008--NUTRACEUTICAL_INTERNATIONAL_CORP |
| 882873--9/20/2007--UROLOGIX_INC |
| 350907--3/16/2006--THORATEC_CORP |
| 882873--9/21/2009--UROLOGIX_INC |
| 1091596--2/26/2007--CYTOMEDIX_INC |
| 1017259--3/29/2010--NMT_MEDICAL_INC |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 811240--3/17/2008--BIOLASE_TECHNOLOGY_INC |
| 1324759--3/31/2010--Cereplast_Inc |
| 350907--4/2/2007--THORATEC_CORP |
| 350907--2/27/2008--THORATEC_CORP |
| 350907--2/27/2009--THORATEC_CORP |
| 943894--3/31/2010--EZENIA_INC |
| 943894--3/24/2009--EZENIA_INC |
| 882873--9/13/2006--UROLOGIX_INC |
| 1006195--3/15/2007--MATRIXX_INITIATIVES_INC |
| 1030206--2/3/2009--VASCULAR_SOLUTIONS_INC |
| 1030206--2/5/2008--VASCULAR_SOLUTIONS_INC |
|